CATALENT ACQUIRES US COMMERCIAL CELL THERAPY FACILITYEstablishing US-based campus to support late-stage and commercial manufacturing for autologous and allogeneic cell therapiesLearn More CATALENT INVESTS $350 MILLION AT BLOOMINGTON, INDIANA SITEExpanding Biomanufacturing and Fill/Finish CapabilitiesLearn More CATALENT ACQUIRES FACILITY IN OXFORDSHIRE TO EXPAND BIOLOGICS CAPABILITIES IN THE UK AND ACROSS EUROPEExpanding Biomanufacturing and Fill/Finish CapabilitiesLearn More DEVELOPING BIOLOGICS DRUGS IS SCIENCEAccelerating Advanced Treatments & Vaccines is Art.Learn More How can we work together BIOLOGICS GENE THERAPY CELL THERAPY TECHNOLOGIES Latest News Catalent Launches UpTempo Virtuoso™ AAV Platform to Reduce Gene Therapy Development Time and Accelerate Path to Clinic UPTEMPO VIRTUOSO™ AAV PLATFORM PROCESS A scalable, CGMP-ready process providing early-stage partners with accelerated timelines for production of their clinical material. LEARN MORE PLASMID DNA Catalent offers plasmid DNA supply and solutions from early-stage lead identification to GMP manufacturing for clinical- and commercial-scale. Gene Therapy Our Gene Therapy team combines leading expertise in viral vector technology and scale-up with state-of-the-art CGMP facilities, including dedicated plasmid DNA manufacturing sites and our FDA approved commercial facility. STRATEGIES TO ACHIEVE SUCCESSFUL COMMERCIAL APPROVAL & LAUNCH Experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the successful launch and approval of a biologic. BIOLOGICS NETWORK Our network of biologics sites provides an integrated approach to get medicines to your patients faster anywhere in the world. LEARN MORE JOIN OUR TEAM Catalent is growing in Biologics and is making significant investments in people in this area. Explore global career opportunities with our Biologics team. NEWS Catalent Launches UpTempo Virtuoso™ AAV Platform to Reduce Gene Therapy Development Time and Accelerate Path to Clinic Catalent Acquires Commercial-Scale Cell Therapy Development and Manufacturing Facility in Princeton, New Jersey, from Erytech Catalent to Invest $350 Million in Integrated Biologics Drug Substance and Drug Product Manufacturing at Bloomington, Indiana, Facility Catalent Acquires Facility in Oxfordshire to Expand Biologics Capabilities in the UK and Across Europe VIEW ALL NEWS EVENTS ON Helix 2022 – Leveraging Proven Technology to Speed Path to First-In-Human Studies with GPEx® Lightning CASSS Bioassays 2022 VIEW ALL EVENTS EXPERT CONTENT Advances in Analytical Technology for Biopharmaceuticals Prefilled Syringes & Parenteral Manufacturing Accelerating Method Transfer: Effective Automation Of Biological Assays VIEW ALL ARTICLES
